Overall, cDC2 contributes to anti-tumor immunity by TAA presentation to CD4+ T cells or the transfer of TAAs to lymphoid tissue-resident DCs but is dependent on cDC1 function and the presence of Tregs [28, 33]. Here, CD4 is linked to neoplasm.